Technical Analysis for CVM - Cel-Sci Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.44 | -0.69% | -0.01 |
Earnings due: May 10
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Doji - Bullish? | Reversal | -0.69% | |
| Wide Bands | Range Expansion | -0.69% | |
| Down 3 Days in a Row | Weakness | -0.69% |
| Alert | Time |
|---|---|
| Outside Day | about 13 hours ago |
| Down 3% | about 13 hours ago |
| Fell Below Previous Day's Low | about 13 hours ago |
| Down 2 % | about 13 hours ago |
| Down 1% | about 14 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/10/2024
Cel-Sci Corporation Description
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company's principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer. The Multikine is an immunotherapeutic agent consisting of a mixture of cytokines that produce an anti-tumor immune response. It also develops Ligand Epitope Antigen Presentation System (LEAPs), a heteroconjugate technology that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, develops a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Immune System Immunotherapy Vaccines Autoimmunity Rheumatoid Arthritis Vaccination Transplantation Cytokine Head And Neck Cancer Antigen Immune Response Allergies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.23 |
| 52 Week Low | 1.04 |
| Average Volume | 290,754 |
| 200-Day Moving Average | 1.95 |
| 50-Day Moving Average | 1.91 |
| 20-Day Moving Average | 1.62 |
| 10-Day Moving Average | 1.50 |
| Average True Range | 0.11 |
| RSI (14) | 29.08 |
| ADX | 43.88 |
| +DI | 6.31 |
| -DI | 23.29 |
| Chandelier Exit (Long, 3 ATRs) | 1.60 |
| Chandelier Exit (Short, 3 ATRs) | 1.73 |
| Upper Bollinger Bands | 1.89 |
| Lower Bollinger Band | 1.35 |
| Percent B (%b) | 0.16 |
| BandWidth | 33.35 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.14 |
| MACD Histogram | 0.001 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.58 | ||||
| Resistance 3 (R3) | 1.57 | 1.53 | 1.55 | ||
| Resistance 2 (R2) | 1.53 | 1.49 | 1.53 | 1.54 | |
| Resistance 1 (R1) | 1.48 | 1.47 | 1.46 | 1.49 | 1.54 |
| Pivot Point | 1.44 | 1.44 | 1.43 | 1.44 | 1.44 |
| Support 1 (S1) | 1.39 | 1.40 | 1.37 | 1.40 | 1.34 |
| Support 2 (S2) | 1.35 | 1.38 | 1.35 | 1.34 | |
| Support 3 (S3) | 1.30 | 1.35 | 1.33 | ||
| Support 4 (S4) | 1.31 |
